27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- GSK plc (NYSE:GSK) has initiated the withdrawal process of the U.S. marketing authorization for Blenrep (belantamab mafodotin-blmf) following the FDA request.
- This request was based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations.
- Blenrep is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.
- Also see: Citing Efficacy, GSK Stops Two Pivotal UTI Antibiotic Trials Early.
- Patients already enrolled in the Blenrep Risk Evaluation, and Mitigation Strategy program will have the option to enroll in a compassionate use program to continue to access treatment.
- Additional trials within the DREAMM clinical trial program are designed to determine the benefit of belantamab mafodotin in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy and dosing optimization to maintain efficacy while reducing corneal events.
- Data from the DREAMM-7 and DREAMM-8 phase 3 trials are event-driven, and results are anticipated in the first half of 2023.
- Price Action: GSK shares are up 0.45% at $33.59 during the premarket session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!